|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
The Sands of Time Cannot be Stilled
The FDA has been implementing several changes in the way it does business, for example, relying on third-party inspections, academia, and industry in many new ways. The implementation of process analytical technology is among these changes.
Advertisement
Articles in this issue
almost 20 years ago
Analytical Instrument Qualificationalmost 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?almost 20 years ago
Team Effortalmost 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedalmost 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionalmost 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressalmost 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefalmost 20 years ago
New Climatealmost 20 years ago
2006: A Regulatory OdysseyAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
ASMS 2026 Award Winners Highlight the Future of Mass Spectrometry
2
Best of the Week: Chromatography Methods, HPLC 2026 Previews, and More
3
A Look at the Major Technical Themes of ASMS 2026
4
Mass Spectrometry Approaches for Investigating Alpha-Synuclein Structural Changes in Neurodegenerative Disease
5